Characterisation of IL-23 receptor antagonists and disease relevant mutants using fluorescent probes

Association of single nucleotide polymorphisms in the IL-23 receptor with several auto-inflammatory diseases, led to the heterodimeric receptor and its cytokine-ligand IL-23, becoming important drug targets. Successful antibody-based therapies directed against the cytokine have been licenced and a class of small peptide antagonists of the receptor have entered clinical trials. These peptide antagonists may offer therapeutic advantages over existing anti-IL-23 therapies, but little is known about their molecular pharmacology. In this study, we use a fluorescent version of IL-23 to characterise antagonists of the full-length receptor expressed by living cells using a NanoBRET competition assay. We then develop a cyclic peptide fluorescent probe, specific to the IL23p19:IL23R interface and use this molecule to characterise further receptor antagonists. Finally, we use the assays to study the immunocompromising C115Y IL23R mutation, demonstrating that the mechanism of action is a disruption of the binding epitope for IL23p19.

The exact sample size (n) for each experimental group/condition, given as as a discrete number and unit of of measurement A statement on on whether measurements were taken from distinct samples or or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of of all covariates tested A description of of any assumptions or or corrections, such as as tests of of normality and adjustment for multiple comparisons A full description of of the statistical parameters including central tendency (e.g. means) or or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or or associated estimates of of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of of freedom and P value noted Give P values as exact values whenever suitable.

For Bayesian analysis, information on on the choice of of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of of the appropriate level for tests and full reporting of of outcomes Estimates of of effect sizes (e.g. Cohen's d, Pearson's r), ), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of of computer code Data collection

Data analysis
For manuscripts utilizing custom algorithms or or software that are central to to the research but not yet described in in published literature, software must be be made available to to editors and reviewers. We We strongly encourage code deposition in in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data
Policy information about availability of of data All manuscripts must include a data availability statement This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or or web links for publicly available datasets -A description of of any restrictions on on data availability -For clinical datasets or or third party data, please ensure that the statement adheres to to our policy S J Hill Apr 13, 2023 Data were collected using a Pherastar plate reader using the associated BMG labtech data acquisition (

Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Methods n/a Involved in the study

ChIP-seq
Flow cytometry MRI-based neuroimaging n/a n/a n/a n/a At least three independent experiments were used to measure each data point. Individual experiments were performed in at least duplicates (technical repeats). Five independent experiments were used for most data sets. Specific numbers of independent experiments are detailed in the figure legends. Sample size was chosen on the basis of the standard deviation obtained in similar plate reader-based experiments.
Individual data points (individual replicates in an experiment) were excluded on very rare occasions. Data were only excluded from analysis if an experimental error was observed during the set up of the experiment (e.g. pipetting mistake) or a measurement indicated that a particular reagent had not been added (e.g. lack of fluorescence for an added fluorescent probe). One one occasion an outlier was excluded from the statistical analysis in Figure 6b following its identification as an outlier using the Grubbs test (with alpha=0.001). The value of the outlier is, however, given in the legend to Figure 6b.
Each individual experiment was repeated at least three times. Individual experiments were done in at least duplicates (technical repeats). Five independent experiments were used for most data sets. Specific numbers of independent experiments are detailed in the figure legends and the Source Data file.
Experimental conditions were randomly allocated as far as possible within the 96-well design.
Blinding of the investigators was not possible for these studies. The transient transfection approach meant that the investigators needed knowledge of the plasmids being used. However, since all data collection was automatic using the PheraStar FS plate reader, observer bias was not considered to be a factor.